Update! Watch a recording of this talk.
This talk is an activity from the FEBS Junior Section, an initiative set up by students and young researchers from some of the FEBS Constituent Societies. Each month a Junior Section from one of the participant Societies organizes an online event on either a research or a career topic. This April talk is organised by HDBMB Young Scientists' Forum, the junior section of the HDBMB.
Speaker: Prof. Igor Stagljar, from the University of Toronto, Canada
Topic: “My story about life, science and success”
Time: 14 April 2022, 19:00 (CET)
For more information, see the presentation abstract below and visit the Stagljar lab webpage.
Prof. Igor Stagljar is a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre, University of Toronto, Canada, and a Co-director and Laboratory Head at the Mediterranean Institute of Life Sciences in Split, Croatia. Professor Stagljar is one of the world leaders in the field of proteomics/chemical genomics, developing high-throughput technologies to facilitate the study of the protein-protein interactions (PPIs) of various human membrane proteins involved in cancer. The research in his lab has led to the development of the Membrane Yeast Two-Hybrid and the Mammalian Membrane Two-Hybrid (MaMTH) technologies, both of which have revolutionized membrane proteomic research. As of recent, Stagljar lab adapted MaMTH into a drug screening platform and has been directing its research efforts into SARS-CoV-2 diagnostics.
In 2015, the University of Toronto honored Prof. Stagljar with "Inventor of the Year” award for his contribution to Canada’s innovation agenda and the advancement of knowledge. As principal investigator, Prof. Stagljar secured over $38 million in research funds since he moved to Canada (in 2005) from a range of national and international funding agencies, non-profit foundations, and pharmaceutical companies. Based on his academic successes, Prof. Stagljar has co-founded two companies, Dualsystems Biotech Inc, a world-leading company in the field of interactive proteomics, and a new Toronto-based biotech start-up company named Perturba Therapeutics.
The FEBS Junior Section
Want to join this platform for young European life scientists? Learn more about our initiative, check out the Room for the FEBS Junior Section and – if you do not have a junior section yet – read this post about how to set one up!
If you have registered to receive emails about FEBS Junior Section events and would like to unsubscribe, please use this form. If you have any problems with the form, contact [email protected]
Join the FEBS Network today
Joining the FEBS Network’s molecular life sciences community enables you to access special content on the site, present your profile, 'follow' contributors, 'comment' on and 'like' content, post your own content, and set up a tailored email digest for updates.